Influenza Vaccine Development

Slides:

Advertisements

Similar presentations

BIRD FLU PANDEMIC PREPAREDNESS.

Advertisements

0 HHS Influenza Vaccine Projects for NVAC Meeting June 7-8, 2005 By: Dr. Robin Robinson (HHS/OPHEP)

Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian virus Vaccine 2007 Huoying Shi, Xiu Fan Liu, Xiaorong Zhang,

Vaccines and Related Biological Products

Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.

Influenza and Influenza Vaccine

Lessons Learned from the Reconstruction of the 1918 Pandemic Adolfo García-Sastre, PhD Professor of Microbiology Mount Sinai School of Medicine.

Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.

Immunoprophylaxis (prophylactic immunization). Immunoprophylaxis Types of immunization Immunoglobulins and vaccines Strategies in vaccine preparation.

CDC Director’s Perspective Immunization Program Managers Meeting Thomas R. Frieden, MD, MPH Director, CDC Administrator, ATSDR.

Clinical Outcomes of Influenza Infection Asymptomatic Asymptomatic Symptomatic Symptomatic  Respiratory syndrome - mild to severe  Involvement of major.

Miriam Nuño Harvard School of Public Health, USA Gerardo Chowell Los Alamos National Laboratory, USA Abba Gumel University of Manitoba, Canada AIMS/DIMACS/SACEMA.

National Vaccine Advisory Committee June 7, 2005 Pandemic Influenza Vaccine Research and Development Linda C. Lambert Chief, Respiratory Diseases Branch.

AVIANAVIAN FLUFLU Ginny Codd Viruses: Infection and Ecology.

Avian Influenza H5N1: Vaccination Against a Pandemic.

National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.

0 HHS Influenza Vaccine Projects for NVAC Meeting November 29-30, 2005 By: Dr. Robin Robinson Sr. Project Officer ORDC/OPHEP/DHHS.

Influenza Vaccination

Adult Immunization 2010 Influenza Segment This material is in the public domain This information is valid as of May 25, 2010.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

INFLUENZA VACCINE Group 1 Zainab Ashfaq Bushra Abbas Ahtasham Danish.

Smallpox and Influenza "In early 1962 long queues attended any clinic in Birmingham offering vaccination, because three patients with smallpox were in.

Preparing for Pandemic Influenza Anna Lönnroth European Commission DG Research: Health Research Priority Medicines for Europe and the World.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

VACCINATION. Vaccination: Is The administration of an antigen to stimulate a protective immune response against an infectious agent.

By Aizaz Khan. Maurice Hilleman discover measle vaccine. Maurice Hilleman Maurice Hilleman's measles vaccine is estimated to prevent 1 million deaths.

Biotechnology VC Funding, Vaccines, Technology. What is Biotechnology? Biotech: refers to the use of living organisms or their products to modify human.

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

NIAID Commitment to Influenza Research and Preparedness F. Gray Handley Associate Director for International Research Affairs National Institute of Allergy.

The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.

Pandemic Influenza; A Harbinger of Things to Come Michael T Osterholm PhD, MPH Director, Center for Infectious Disease Research and Policy Associate Director,

Learning from the 2009 H1N1 Pandemic Response 1 Daniel S. Miller MD, MPH Director, International Influenza Unit Office of the Secretary Office of Global.

Infection.... Our ViIlain.  There are three main types of Influenza Viruses. (many strains)  Type A  Type B  Type C – Not clinically important in.

VRBPAC 25 February 2011 Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

The Flu Rapid Reading Exercise. The Flu Every year, 10 percent to 20 percent of Americans get sick with the flu (influenza). For most people, the fever,

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

Update on Pandemic Vaccine Development 3 rd WHO WPRO/SEARO NIC Meeting August, 2009, Beijing Masato Tashiro, MD., PhD. Director, WHO Collaborating.

Food and Drug Administration

Influenza Today Joseph Mester, Ph.D. September 24, 2009.

Avian Influenza When avian influenza hits will science have an efficient vaccine?

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group One: Influenza Virulence and Antigenic.

Global Pandemic Preparedness Research Efforts text Klaus Stöhr WHO Global Influenza Programme 3 Today  Medium-term applied research linked to medical.

Virion Structure and Organization

FDA/CBER Vaccines and Related biological Products Advisory Committee Meeting Discussion of Clinical Trials to Support use of Vaccines against the 2009.

INFLUENZA UPDATE DEBBYE ROSEN ADULT IMMUNIZATION COORDINATOR CONNECTICUT DEPARTMENT OF PUBLIC HEALTH

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Five: Immunology, Assay Standardization,

Influenza A (H1N1) Vaccine Vaccines and Related Biological Products Advisory Committee Meeting, 23 July 2009 Raburn Mallory, M.D. Proprietary Vaccines.

ORTHOMYXOVIRIDAE- INFLUENZA VIRUSES PETER H. RUSSELL, BVSc, PhD, FRCPath, MRCVS Department of Pathology and Infectious Diseases, The Royal Veterinary College,

Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY.

Pandemic Vaccines Current and Future Issues 30 January 2007 Beijing Keiji Fukuda Global Influenza Programme.

FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Two: Controlling Animal Influenza.

NVAC Influenza Working Group Vaccine Research, Development and Production.

Biotechnology Vaccines Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:

Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting September 27, 2006 Barbara L. Mulach, Ph.D. National Institute.

Update on the Development of a Group A Streptococcal Vaccine Fran A. Rubin, Ph.D. Program Officer for Group A Streptococci Respiratory Diseases Branch.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/22/2010) Jerry P. Weir, Ph.D., Director.

1 H5N1 Influenza Virus Vaccine, A/Vietnam/1203/2004 (Clade 1) VRBPAC Presentation Kenneth P. Guito, MBA Strategic Project Office.

1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.

Epidemiology of Swine Influenza H1N1 Amman 5/5/2009 Dr. Labib Sharif Associate Prof. Of Epidemiology Faculty of Veterinary Medicine Jordan University of.

Novartis Vaccines - Influenza A H1N1v vaccine development Theodore F Tsai MD MPH July 23, 2009 DHHS supported influenza cell culture vaccine production.

Marketing Authorisation & Yearly Licence of Influenza Vaccines - „Mock-up” & Pre-Pandemic Influenza Vaccines Zsuzsanna Pauliny MD

1 Considerations in the Pre- and Early Pandemic Use of Influenza Vaccine Jesse L. Goodman, MD, MPH Center for Biologics Evaluation and Research, VRBPAC,

EXPLORING INFLUENZA VACCINE PRODUCTION TECHNOLOGIES- PRESENT AND FUTURE Gaurav Gupta, Zydus Cadila, Ahmedabad.

Pandemic Influenza Vaccine Manufacture Preparedness Lin Su Sinovac Biotech Co., Ltd.

Viral vaccines .

ACIP Recommendations Update for the U.S. Influenza Season

Influenza Vaccines MedCh 401 Lecture 5 19May06 KL Vadheim Lecture 4.

VACCINATION. Vaccination: Is The administration of an antigen to stimulate a protective immune response against an infectious agent.

Influenza algorithm for determining recommended 2009–2010 influenza immunization. a Contraindications: please refer to page 7 of the policy statement for.

Presentation transcript:

Influenza Vaccine Development Cristina Cassetti, Ph.D. Influenza Program Officer Division of Microbiology and Infectious Diseases NIAID

NIAID Research Pathway

Vaccines currently available Trivalent inactivated vaccine (TIV) Live attenuated vaccine (LAIV) Both vaccines target primarily the anti-HA antibody response and are made by: generating a high growth reference virus (classical reassortment). growing the vaccine in embryonated chicken eggs.

Advantages of current influenza vaccines TIV first licenced in US in 1945. 70-90% efficacy in healthy adults (in preventing influenza) Dramatically reduce complications from influenza, including hospitalization and death. Can reduce the risk for outbreaks by inducing herd immunity.

Limitation of current vaccines A new vaccine has to be generated every year . The vaccine strains for the upcoming influenza season have to be predicted at least 6 months in advance. Classical reassortment technology is cumbersome and sometimes does not lead to the ideal reference virus. Classical reassortment requires availability of an acceptable clinical isolate. Vaccine manufacturing relies on the availability of hundreds of millions of embryonated chicken eggs. TIV has limited efficacy in the elderly (30% to 40% efficacy in preventing influenza)

NIAID-supported research for the development of new influenza vaccines I Strategies to develop vaccines that have enhanced immunogenicity or are broadly-protective: Improve TIV with adjuvants, mucosal delivery or increased dose. New vaccines that target conserved proteins (NP and M2) Ongoing clinical studies to elucidate the immune responses to LAIV compared to TIV and natural infection (Arvin, CA).

NIAID-supported research for the development of new influenza vaccines II Establishment of reverse genetics technology in ’99. Potentially faster and easier to generate of vaccine reference strains (currently being used to make Vietnam H5N1 reference viruses). Eliminates the need for working directly with the clinical isolate. Can engineer HA of pandemic virus strains without the basic amino acids at the cleavage site (associated with high virulence).

NIAID-supported research for the development of new influenza vaccines NIAID-supported research for the development of new influenza vaccines. III New technologies for the rapid production of influenza vaccines: Tissue culture-based system (as alternative to eggs) DNA-based vaccines Recombinant baculovirus-expressed protein vaccines New methods for vaccine delivery: Skin patch Gene gun

NIAID’s commitment to further develop influenza vaccines Biodefence research opportunities Challenge grants Small Business biodefence program Contracts: Pre-clinical development (VRPRU) DMID supported clinical trial network (VTEUs) Repository for influenza reagents Pandemic preparedness in Asia: Reference strain library (2003 H5N1; 2003 H7N7; 2004 H5N1 currently being developed)